ReviewFrontiers in immunology2026
Enteric neuro-immune-tumor ecosystem in pancreatic, colorectal, and gastric malignancies: context dependence and translational priorities.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma, colorectal cancer, and gastric cancer arise in densely innervated tissues, yet neural regulation remains incompletely integrated into tumor immunology. This narrative review uses the term "enteric neuro-immune-tumor ecosystem" for an operational framework comprising five anatomy-anchored evidence domains: local enteric nervous system remodeling, extrinsic autonomic and sensory regulation, perineural invasion-associated niches, glial-cell-mediated signaling, and microbiota-neuro-immune communication. Hepatocellular carcinoma and cholangiocarcinoma are treated as a labeled hepatobiliary extension. Evidence is described consistently as GI-direct evidence, GI-physiology evidence, or cross-tumor evidence and is interpreted separately from study maturity and translational status. Available studies indicate context-dependent associations or effects of sympathetic, parasympathetic, sensory, and glial signals on CD8+ T-cell function, myeloid-cell states, stromal organization, and cancer-cell state; the direction and magnitude vary with tumor type, disease stage, anatomical site, neural subtype, and receptor-bearing cell. Cancer-induced nerve injury is associated with IL-6- and type I interferon-related inflammation and dysfunctional antitumor immunity, whereas selected cholinergic and sympathetic circuits can restrain tumor growth in specific preclinical models. Candidate interventions, including β-adrenergic blockade, NGF/Trk inhibition, denervation, and neurotoxin-based approaches, are supported mainly by preclinical studies or retrospective associations. Prospective tumor-specific evidence and validated selection biomarkers remain limited, and none of these interventions has an approved oncologic indication for neuro-immune modulation. A context- and evidence-matched approach may help define when neural targeting merits clinical testing and when it could disrupt protective neural functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.